Teva Pharmaceutical Industries: Short Interest Falls 6.62% Amid Decline in Shorted Shares

Teva Pharmaceutical Industries' (TEVA) short interest has fallen 6.62% since its last report, with 49.89 million shares sold short, representing 4.37% of all regular shares available for trading. This decline in short interest may indicate a decrease in bearish sentiment towards the company. TEVA's peer group average for short interest is 3.06%, which is higher than most of its peers.

Teva Pharmaceutical Industries' (TEVA) short interest has fallen 6.62% since its last report, with 49.89 million shares sold short, representing 4.37% of all regular shares available for trading. This decline in short interest may indicate a decrease in bearish sentiment towards the company [1].

As of July 15, 2025, the short interest ratio (days to cover) for TEVA was 4.6, indicating that it would take 4.6 days of the average trading volume of 12.19 million shares to cover all short positions [1]. This ratio is higher than the industry average, suggesting a higher level of uncertainty or pessimism among investors. However, the recent decline in short interest could signal a shift towards more positive sentiment.

Teva's peer group average for short interest is 3.06%, which is higher than most of its peers. Companies such as Moderna, Inc. (19.34%) and Insmed, Inc. (5.11%) have significantly higher short interest ratios, indicating more bearish sentiment towards these companies [1].

The decline in short interest is also notable in the context of recent institutional trading activity. Invesco Ltd., for instance, reduced its stake in TEVA by 22.7% in the first quarter of 2025, selling 1,377,277 shares [2]. This reduction could indicate a change in Invesco's outlook on TEVA's prospects.

Moreover, several analysts have recently upgraded their ratings for TEVA, suggesting a more favorable outlook. Hsbc Global Res, Truist Financial, and Wall Street Zen have all given TEVA a "buy" rating, while Goldman Sachs and JPMorgan Chase have also raised their target prices [2]. This positive analyst sentiment could contribute to the decrease in short interest.

In conclusion, the decline in Teva Pharmaceutical Industries' short interest indicates a potential shift in investor sentiment towards the company. While the short interest ratio remains relatively high, the recent decrease suggests a decrease in bearish sentiment. This trend should be monitored closely, as it could have significant implications for TEVA's stock price.

References:
[1] https://www.marketbeat.com/stocks/NYSE/TEVA/short-interest/
[2] https://www.marketbeat.com/instant-alerts/filing-invesco-ltd-sells-1377277-shares-of-teva-pharmaceutical-industries-ltd-nyseteva-2025-08-17/